ARTICLE | Company News
Durect, Impax deal
January 20, 2014 8:00 AM UTC
Durect granted Impax exclusive, worldwide rights to develop and commercialize Eladur bupivacaine to treat pain associated with postherpetic neuralgia (PHN). Durect will receive $2 million up front an...